SCHEMBL18713232

SCHEMBL18713232

CN1CC2CC(C1)N2Cc1cccnc1

nearest known ligand 0.67

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.47
CHRNA4 P43681 1/20 0.47
CHRM2 P08172 2/20 0.46
CHRM1 P11229 2/20 0.46
CHRM3 P20309 2/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 1/20 0.45
OPRM1 P35372 1/20 0.43
OPRK1 P41145 1/20 0.43
KCNH2 Q12809 1/20 0.43
CYP11B1 P15538 1/20 0.43
RET P07949 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29615707 0.91 CHRM2 (0.49) CHRNB2CHRNA4CHRM2CHRM1CHRM3
SCHEMBL18713233 0.85 CHRNB2 (0.49) CHRNB2CHRNA4KDM4EOPRM1OPRK1
SCHEMBL18705130 0.84 CHRNB2 (0.44) CHRNB2CHRNA4KDM4EALDH1A1OPRM1
SCHEMBL20148615 0.84 CHRNB2 (0.44) CHRNB2CHRNA4KDM4EALDH1A1OPRM1
SCHEMBL18390147 0.80 CHRM2 (0.58) CHRNB2CHRNA4CHRM2CHRM3ALDH1A1
SCHEMBL22031240 0.79 RET (0.43) CHRNB2CHRNA4CHRM1KDM4EALDH1A1
SCHEMBL29615784 0.77 CHRNB2 (0.57) CHRNB2CHRNA4CHRM2CHRM1CHRM3
SCHEMBL29615483 0.77 TLR7 (0.46) CHRNB2CHRNA4CHRM2CHRM1CHRM3
SCHEMBL22812025 0.76 ALDH1A1 (0.48) CHRNB2CHRNA4ALDH1A1RET
SCHEMBL22812010 0.76 RET (0.43) CYP11B1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 US disclosed
US-10953005-B1 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-03-23 US disclosed
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2017-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF CHRNB2 2323/4885CHRNA4 1901/4885CHRM2 3155/4885
US-10953005-B1 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF CHRNB2 2276/4885CHRNA4 1977/4885CHRM2 3260/4885
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF CHRNB2 2276/4885CHRNA4 1977/4885CHRM2 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.